Indication
Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Loading your page…
Loading your page…
Prostatic Neoplasms
Marketing Authorisation Holder: Accord Healthcare S.L.U.
EMA Authorisation: 24/05/2022
INN: leuprorelin
AI Drug & Interaction Analysis
Free account required
Ask Osler about Camcevi: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.